NTRB

MKT CAP:$49M

Nutriband Inc.

Market Cap

$49M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$4.01-$0.42 (-9.48%)

Apr 23, 2026

Company Details

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-...

CEO

Gareth Sheridan

IPO Date

Oct 1, 2021

Website

nutriband.com

Key Metrics TTM

Revenue

$2M

+12.7% YoY

Net Income

-$13M

EPS (Diluted)

-$3.07

Free Cash Flow

-$6M

Revenue / Share

$0.19

Gross Margin

32.6%

Operating Margin

-406.5%

Net Margin

-560.8%

FCF Margin

-247.4%

P/S

21.5x

P/E

—

Earnings Reports

Q4 2025

Apr 27, 2026

PENDING

Q3 2025

Dec 10, 2025

$346.1K-46.4%EPS -$0.32

Q2 2025

Sep 9, 2025

$622.5K+40.6%EPS -$2.12

Q1 2025

May 30, 2025

$667.4K+63.4%EPS -$0.12

FY 2024

Apr 28, 2025

$2M+2.6%EPS -$0.99

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q3 21	$283.0K	$109.3K	-$2M
Q4 21	$491.9K	$103.3K	-$4M
Q2 22	$456.1K	$151.8K	-$1M
Q3 22	$618.0K	$268.7K	-$1M
Q4 22	$527.5K	$129.4K	-$2M
Q1 23	$476.9K	$222.3K	-$1M
Q2 23	$655.9K	$299.7K	-$824.2K
Q3 23	$427.8K	$158.9K	-$2M
Q4 23	$524.6K	$170.2K	-$1M
Q1 24	$408.5K	$154.2K	-$2M
Q2 24	$442.8K	$90.8K	-$1M
Q3 24	$645.8K	$179.6K	-$1M
Q4 24	$642.4K	$274.6K	-$2M
Q1 25	$667.4K	$243.5K	-$1M
Q2 25	$622.5K	$156.9K	-$2M
Q3 25	$346.1K	$68.5K	-$4M

Valuation

Quarter	P/S	P/E
Q3 21	32.4x	—
Q4 21	24.2x	—
Q2 22	23.6x	—
Q3 22	18.1x	—
Q4 22	14.0x	—
Q1 23	12.6x	—
Q2 23	13.4x	—
Q3 23	8.0x	—
Q4 23	10.7x	—
Q1 24	15.5x	—
Q2 24	44.9x	—
Q3 24	34.6x	—
Q4 24	38.3x	—
Q1 25	27.1x	—
Q2 25	34.8x	—
Q3 25	30.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	-$1M	-$1M
Q4 21	-$1M	-$1M
Q2 22	-$908.5K	-$932.7K
Q3 22	-$520.4K	-$521.7K
Q4 22	-$814.0K	-$824.0K
Q1 23	-$749.9K	-$752.5K
Q2 23	-$995.1K	-$995.1K
Q3 23	-$1M	-$1M
Q4 23	-$718.2K	-$767.4K
Q1 24	-$833.9K	-$840.1K
Q2 24	-$2M	-$2M
Q3 24	-$1M	-$1M
Q4 24	-$1M	-$1M
Q1 25	-$1M	-$1M
Q2 25	-$1M	-$1M
Q3 25	-$2M	-$2M

Capital Expenditures

Quarter	CapEx
Q3 21	$2.0K
Q4 21	$30.2K
Q2 22	$24.2K
Q3 22	$1.3K
Q4 22	$10.0K
Q1 23	$2.6K
Q2 23	$0
Q3 23	$0
Q4 23	$49.1K
Q1 24	$6.2K
Q2 24	$38.9K
Q3 24	$47.0K
Q4 24	$0
Q1 25	$0
Q2 25	$5.3K
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q3 21	-27.8%	+320.9%
Q4 21	+41.3%	+68.7%
Q2 22	+5.2%	+99.1%
Q3 22	+189.1%	+142.8%
Q4 22	+86.4%	+21.4%
Q1 23	-3.0%	-65.0%
Q2 23	+43.8%	-0.7%
Q3 23	-30.8%	+27.3%
Q4 23	-0.6%	-17.2%
Q1 24	-14.3%	+53.7%
Q2 24	-32.5%	+25.2%
Q3 24	+50.9%	-3.7%
Q4 24	+22.4%	+42.4%
Q1 25	+63.4%	-9.5%
Q2 25	+40.6%	+41.7%
Q3 25	-46.4%	+103.9%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$529.4K	187.0%
Q4 21	$610.3K	124.1%
Q2 22	$0	0.0%
Q3 22	$405.2K	65.6%
Q4 22	$0	0.0%
Q1 23	$162.1K	34.0%
Q2 23	$0	0.0%
Q3 23	$580.6K	135.7%
Q4 23	-$499.9K	-95.3%
Q1 24	$423.0K	103.5%
Q2 24	$130.4K	29.4%
Q3 24	$0	0.0%
Q4 24	-$420.0K	-65.4%
Q1 25	$63.4K	9.5%
Q2 25	$41.0K	6.6%
Q3 25	$63.4K	18.3%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q3 21	$161.0K	—	$1M
Q4 21	$250.4K	—	$1M
Q2 22	$277.9K	—	$908.2K
Q3 22	$290.7K	$1M	—
Q4 22	$295.8K	—	$1M
Q1 23	$400.4K	—	$839.7K
Q2 23	$445.1K	—	$678.7K
Q3 23	$551.5K	—	$1M
Q4 23	$563.4K	—	$913.2K
Q1 24	$974.5K	—	$1M
Q2 24	$774.0K	—	$726.6K
Q3 24	$880.8K	—	$725.7K
Q4 24	$489.9K	—	$2M
Q1 25	$683.4K	—	$973.6K
Q2 25	$562.6K	—	$2M
Q3 25	$457.1K	—	$3M

Revenue by Geography

Quarter	United States	Foreign Member
Q2 22	$456.1K	—
Q4 22	$525.5K	—
Q1 23	$476.9K	—
Q2 23	$655.9K	—
Q3 23	$427.8K	—
Q4 23	$524.6K	—
Q1 24	$408.5K	—
Q2 24	$442.8K	—
Q3 24	$645.8K	—
Q4 24	$642.4K	—
Q1 25	$667.4K	—
Q2 25	$614.9K	$7.6K

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$5M	$0	$5M
Q1 22	$4M	$0	$4M
Q2 22	$3M	$0	$3M
Q3 22	$3M	$0	$3M
Q4 22	$2M	$0	$2M
Q1 23	$1M	$0	$1M
Q2 23	$2M	$0	$2M
Q3 23	$1M	$0	$1M
Q4 23	$492.9K	$0	$492.9K
Q1 24	$8M	$0	$8M
Q2 24	$7M	$0	$7M
Q3 24	$6M	$0	$6M
Q4 24	$4M	$0	$4M
Q1 25	$3M	$0	$3M
Q2 25	$7M	$0	$7M
Q3 25	$5M	$0	$5M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q3 21	8M	-12.3%	+17.9%
Q4 21	8M	0.0%	+18.0%
Q2 22	10M	+29.3%	+32.9%
Q3 22	8M	-20.5%	-9.8%
Q4 22	8M	+0.4%	+3.2%
Q1 23	8M	+0.0%	+3.2%
Q2 23	8M	0.0%	-20.2%
Q3 23	8M	0.0%	+0.4%
Q4 23	8M	+4.6%	+4.6%
Q1 24	9M	+11.8%	+16.9%
Q2 24	11M	+20.8%	+41.2%
Q3 24	11M	+0.4%	+41.7%
Q4 24	11M	-4.5%	+29.4%
Q1 25	11M	+4.9%	+21.5%
Q2 25	11M	+0.8%	+1.4%
Q3 25	12M	+7.5%	+8.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q3 21	$56.6K	5
Q4 21	$37.8K	13
Q2 22	$35.1K	13
Q3 22	$47.5K	13
Q4 22	$40.6K	13
Q1 23	$36.7K	13
Q2 23	$50.5K	13
Q3 23	$32.9K	13
Q4 23	$260	2K
Q1 24	$202	2K
Q2 24	$219	2K
Q3 24	$320	2K
Q4 24	$318	2K
Q1 25	$330	2K
Q2 25	$308	2K
Q3 25	$171	2K

Revenue / Employee